|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Homeobox D10 (HOXD10) is a member of the homeobox (HOX) gene family and has been reported to act as a tumor suppressor.
|
30938888 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the HOXD10 gene may act as a tumor suppressor in PTC.
|
29115628 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
HOXD10 methylation was significantly associated with vessel cancerous embolus, tumor cell differentiation, and the 3-year overall survival rate (all <i>P</i> < 0.05).
|
29075359 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HoxD10 gene plays a critical role in cell proliferation in the process of tumor development.
|
28231752 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma.
|
26260613 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hoxd10 was highly expressed in gastric cancer and correlated with size of tumor, Lauren classification, depth of invasion, lymph node and distant metastasis, Tumor-Node-Metastasis (TNM) stage, and prognosis.
|
26311318 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MiR‑10b levels were markedly elevated in lymph node metastasis-positive tumor tissue compared with those in lymph node metastasis-free tumor tissue, and were correlated with a downregulation in Hoxd10 expression.
|
25606801 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Utilizing patient tumor samples a significant association was found between immunohistochemical staining of HOXD10 and both the overall and the disease-specific survival, adding further support that HOXD10 is dysregulated in head and neck cancer.
|
25301728 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results confirm the presence of three significantly upregulated (>4-fold) homeobox genes (HOXA5, HOXD10 and HOXD11) in OSCC that may play a significant role in the pathogenesis of these tumors.
|
22227861 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggest that HoxD10 functions as a candidate tumor suppressor in gastric cancer, which is inactivated through promoter hypermethylation.
|
22160393 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrate that anti-miR-10b inhibitor not only enhances HOXD10 expression but also abrogates HA/CD44-mediated tumor cell behaviors in breast tumor cells.
|
20843787 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggest that HoxD10 has tumor-suppressive functions for mammary epithelial cells.
|
16103068 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HoxD10 expression was higher in quiescent as compared to tumor-associated angiogenic endothelium.
|
12466126 |
2002 |